Business ❯ Pharmaceuticals ❯ Biotechnology

Acquisitions

Vertex Pharmaceuticals Sanofi Dark Blue Therapeutics Roche Novo Nordisk Mirum Pharmaceuticals

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

The purchase brings a first-in-class MLLT1/3 protein degrader into Amgen’s oncology research.

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion